Obstetrics & Gynecology Doctors in Lebanon, MO Accepting Medicare

4 Obstetrics & Gynecology doctors found. Showing 1 - 4

Dr. Debra Ann Carson, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 120 Hospital Dr Ste 225, Lebanon, MO 65536 Phone: 417-533-6710

Denis E Percell, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 120 Hospital Dr, Suite 225, Lebanon, MO 65536 Phone: 417-533-6710    Fax: 417-533-6719

Dr. Donald E. Hicks, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 120 Hospital Dr, Suite 225, Lebanon, MO 65536 Phone: 417-533-6710    Fax: 417-533-6719

Dr. William Frank Williams, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 120 Hospital Dr, Suite 225, Lebanon, MO 65536 Phone: 417-533-6710    Fax: 417-533-6719

News Archive

USF receives grant for studying ways to protect fetal brain from maternal infection

University of South Florida (USF) neuroscientists have been awarded a $400,000 federal grant to study ways of protecting the developing fetal brain from the damaging effects of maternal infections, a suspected cause for certain types of autism.

Discovery of mechanisms causing portal hypertension

A physician-scientist at UT Southwestern Medical Center and his research team have identified mechanisms causing a potentially deadly type of hypertension that results from liver damage – findings that could lead to its prevention.

A-Life Medical ranked #2513 on 2010 Inc. 500|5000 list of fastest-growing, private companies

A-Life Medical, Inc., the pioneer and leading provider of computer-assisted coding (CAC) products and services to the healthcare industry, announced today it has been included in the 2010 Inc. 500|5000 list of the fastest-growing, private companies in America. A-Life Medical ranked 2513 in its inaugural appearance on the list.

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

New approach to drug design may yield more effective and less toxic cancer medicines

A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco (UCSF) and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.

Read more Medical News

› Verified 7 days ago